Literature DB >> 8958298

Iron overload in patients with chronic hepatitis C: a clinicopathologic study.

S Haque1, B Chandra, M A Gerber, A S Lok.   

Abstract

Recent studies suggest that increased hepatic iron may impair the response to interferon therapy in patients with chronic hepatitis C. We reviewed the records and liver biopsies of 72 patients with chronic hepatitis C to determine the prevalence of iron overload and to evaluate whether there is a correlation between serum and hepatic iron concentrations and activity of liver disease. Patients with other causes of liver disease or iron overload were excluded. Necroinflammatory activity and fibrosis were evaluated using modified Knodell score. Hepatic iron was assessed using Brissot's grading system. Increased serum iron and ferritin levels were found in 29% and 43% patients, respectively. Hepatic iron grades 0, I, II, III, and IV were present in 37%, 35%, 25%, 3%, and 0% of patients, respectively. A significant correlation was found between hepatic iron grade and serum ferritin (P = .0001). There was no correlation between hepatic iron grade and histological activity index or fibrosis score. In summary, we found a high proportion of patients with chronic hepatitis C had mild to moderate increase in hepatic iron content even when patients with alcoholism and recurrent transfusions were excluded. However, very few patients had severely increased iron load.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958298     DOI: 10.1016/s0046-8177(96)90337-8

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

1.  Identification of treatment efficacy-related host factors in chronic hepatitis C by ProteinChip serum analysis.

Authors:  Naoki Fujita; Mamoru Nakanishi; Jun Mukai; Yuuji Naito; Takafumi Ichida; Masahiko Kaito; Toshikazu Yoshikawa; Yoshiyuki Takei
Journal:  Mol Med       Date:  2010-10-05       Impact factor: 6.354

Review 2.  Interaction between hepatitis C virus and metabolic factors.

Authors:  Yasunori Kawaguchi; Toshihiko Mizuta
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 3.  What is expected from the pathologist in the diagnosis of viral hepatitis?

Authors:  Helmut Denk
Journal:  Virchows Arch       Date:  2011-02-26       Impact factor: 4.064

4.  Iron increases translation initiation directed by internal ribosome entry site of hepatitis C virus.

Authors:  Hana Cho; Hyung Chul Lee; Sung Key Jang; Yoon Ki Kim
Journal:  Virus Genes       Date:  2008-06-20       Impact factor: 2.332

5.  Iron, hepatitis C virus, and hepatocellular carcinoma: iron reduction preaches the gospel for chronic hepatitis C.

Authors:  Naoki Fujita; Yoshiyuki Takei
Journal:  J Gastroenterol       Date:  2007-11       Impact factor: 7.527

6.  Assessment of hepatic fibrosis in pediatric cases with hepatitis C virus in Egypt.

Authors:  Manal A El-Hawary; Mona S El-Raziky; Gamal Esmat; Hanan Soliman; Amr Abouzied; Maissa El-Raziky; Wafaa El-Akel; Rokaya El-Sayed; Fatma Shebl; Abdel-Aziz Shaheen; Hanaa El-Karaksy
Journal:  World J Gastroenterol       Date:  2007-05-28       Impact factor: 5.742

7.  Identification of transferrin receptor 1 as a hepatitis C virus entry factor.

Authors:  Danyelle N Martin; Susan L Uprichard
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-10       Impact factor: 11.205

8.  High prevalence of haemosiderin accumulation in the cytoplasm of gastric glands in patients with liver cirrhosis.

Authors:  H Hattori
Journal:  J Clin Pathol       Date:  2004-06       Impact factor: 3.411

9.  The effect of hepatitis C virus infection on insulin resistance in chronic haemodialysis patients.

Authors:  Ali Ozdemir; Berrin Yalinbas; Umut Selamet; Meltem Eres; Funda Turkmen; Fatma Kumbasar; Berna Murat; A Tayfun Keskin; Yildiz Barut
Journal:  Yonsei Med J       Date:  2007-04-30       Impact factor: 2.759

10.  Nutrition therapy for liver diseases based on the status of nutritional intake.

Authors:  Kenichiro Yasutake; Motoyuki Kohjima; Manabu Nakashima; Kazuhiro Kotoh; Makoto Nakamuta; Munechika Enjoji
Journal:  Gastroenterol Res Pract       Date:  2012-11-14       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.